Matthew Lindsley

Lieutenant and Research Nurse Matt Lindsley shares his experiences and public service role

Jul 8, 2020

Matthew Lindsley, MPH, MSN, RN PHNA-BC, is a Lieutenant in the United States Public Health Service. As a Research Nurse Specialist for the NCI’s Center for Cancer Research, Neuro-Oncology Branch, Matt helps patients with brain and spine tumors who come to NIH for treatment. He was recently deployed to aid in the COVID-19 response mission in Washington state for a number of weeks.  Read more...

Glioblastoma chromosomes

Clinical trial tests combination therapy for glioblastoma multiforme

Jul 7, 2020

Glioblastoma multiforme (GBM) is a type of brain cancer where treatments include radiation therapy, chemotherapy and surgery, but survival rates are poor. Investigators are testing an anticancer drug selinexor, which may make GBM cells less resistant to radiation therapy and allow radiation therapy to kill more cancer cells. Read more...

HIV cell

Trial shows aggressive cancer treatment is appropriate for people with HIV-associated primary central nervous system lymphoma

Jul 2, 2020

New research from CCR scientists shows that chemoimmunotherapy with antiretroviral therapy can lead to long-lasting remissions of HIV-associated primary central nervous system lymphoma without compromising neurocognitive function. Read more...

Antibody-dependent cell-mediated cytotoxicity

Clinical trial studies combination therapy for certain mature T-cell cancers that have not responded to treatment

Jul 1, 2020

Adult T-cell leukemia/lymphoma (ATLL) and mycosis fungoides/Sézary syndrome (MF/SS) are fast-growing cancers that form in T cells, a type of white blood cell that is key to the body’s immune response. A clinical trial is being conducted at the NIH Clinical Center to test a combination therapy for these rare cancers. Read more...

Patient scan

Clinical trial tests targeted radioactive agent as therapy for metastatic prostate cancer

Jun 26, 2020

Prostate-specific membrane antigen (PSMA) is present on the surface of all prostate cancer cells but is highly expressed on cells of castration-resistant prostate cancer (mCRPC). Frank Lin, M.D., Investigator in the the Molecular Imaging Program, is leading NCI’s effort to study the effect of targeted treatment with a radioactive agent to test dosing and overall effect for these patients. Read more...

Christina Annunziata

A Conversation with Christina Annunziata, M.D., Ph.D.

Jun 25, 2020

Christina Annunziata, M.D., Ph.D., is an Investigator in the Women’s Malignancies Branch at the Center for Cancer Research. She has spent most of her career studying the molecular underpinnings of ovarian cancer with the goal of discovering novel treatments. In our Q&A, Dr. Annunziata discusses her personal and professional milestones as well as new directions for her research. Read more...

Microbe

Clinical trial studies immunotherapy for head and neck cancer caused by HPV

Jun 24, 2020

Head and neck cancer caused by the human papillomavirus is being studied in a clinical trial led by Christian S. Hinrichs, M.D., Senior Investigator in the Genitourinary Malignancies Branch. This study will evaluate T-cell immunotherapy for safety without delaying standard treatments (surgery or radiation with chemotherapy). Read more...

CAR T-cell therapy

Clinical trial studies CAR T-cell therapy for relapsed/refractory acute myeloid leukemia

Jun 22, 2020

Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow, the soft inner part of long bones where new blood cells are made. With AML, bone marrow cells don't grow the way they're supposed to. Instead, immature bone marrow cells grow uncontrollably and build up in the body. This study is testing the effect of chimeric antigen receptor T cells (CAR T cells) for children and young adults. Read more...

Peritoneal carcinomatosis

New clinical trial evaluates chemotherapy delivery for stomach cancer

Jun 18, 2020

A clinical trial testing chemotherapy delivery for stomach cancer that has spread to the lining of abdominal cavity is underway at the NIH Clinical Center. Investigators are evaluating how this delivery may improve outcomes for patients with this rare condition. Read more...

Burkitt lymphoma

Study confirms effective, less toxic alternative to standard treatment for adults with Burkitt lymphoma

May 27, 2020

In a new study, an alternative treatment regimen that is less toxic than standard dose-intensive chemotherapy was found to be highly effective for adults with Burkitt lymphoma across all age groups and independent of HIV status. In addition to being better tolerated, the regimen, called dose-adjusted (DA) EPOCH-R, is already an option for diffuse large B-cell lymphomas and can be administered in an outpatient setting. The study was led by researchers in the Center for Cancer Research, and the DA-EPOCH-R regimen was originally developed by researchers led by Wyndham Wilson, M.D., Ph.D., Senior Investigator in the Lymphoid Malignancies BranchRead more...

Pages